Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 3, 2005, Pages 317-319

  Carillo Muñoz, Alfonso Javier ^a   Quindós, Guillermo ^b   Ruesga, Maite ^b   Alonso, Rocío ^b   del Valle, Oscar ^c   Hernández Molina, Juan Manuel ^d   McNicholas, Paul ^e   Loebenberg, David ^e   Santos, Patricia ^f  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL LA INMACULADA   (Spain)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Candida; Opportunistic; Susceptibility

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; POSACONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; OROPHARYNX; THRUSH; YEAST;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

EID: 15844411100     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki022     Document Type: Article

References (28)

1. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G. et al. (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobial Agents and Chemotherapy 47, 3149-54.
2. Barchiesi, F., Schimizzi, A. M., Caselli, F. et al. (2001). Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy 48 769-73.
3. Cacciapuoti, A., Loebenberg, D., Corcoran, E. F., Jr et al. (2000). In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy 44, 2017-22.
4. Cantón, E., Pemán, J., Orero, A. et al. (2002). In vitro activity of posaconazole against yeasts isolated in blood cultures. Revista Española Quimioterapia 15, 341-5.
5. Carrillo, A. J. & Guarro, J. (2001). In vitro activities of four novel triazoles against Scedosporium spp. Antimicrobial Agents and Chemotherapy 45, 2151-3.
6. Connolly, P., Wheat, L. J., Schnizlein-Bick, C. et al. (2000). Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrobial Agents and Chemotherapy 44, 2604-8.
7. Espinel-Ingroff, A. (1998). Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Journal of Clinical Microbiology 36, 2950-6.
8. Galgiani, J. N. & Lewis, M. L. (1997). In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrobial Agents and Chemotherapy 41, 180-3.
9. González, G. M., Tijerina, R., Najvar, L. K. et al. (2002). In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrobial Agents and Chemotherapy 46, 1352-6.
10. Law, D., Moore, C. B. & Denning, D. W. (1997). Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrobial Agents and Chemotherapy 41, 2310-1.
11. Marco, F., Pfaller, M. A., Messer, S. A. et al. (1998). In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopathologia 141, 73-7.
12. Pfaller, M. A., Diekema, D. J., Messer, S. A. et al. (2003). In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. Journal of Clinical Microbiology 41, 78-83.
13. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2002). Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and AMB against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrobial Agents and Chemotherapy 46, 1032-7.
14. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2001). In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and FLZ against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 45, 2862-4.
15. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (1998). In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrobial Agents and Chemotherapy 42, 3242-4.
16. Pfaller, M. A., Messer, M. A. & Jones, R. N. (1997). Activity of a new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrobial Agents and Chemotherapy 41, 233-5.
17. Quindós, G., Carrillo-Muñoz, A. J., Arévalo, M. P. et al. (2000). Susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 46, 395-401.
18. Rubio-Calvo, M. C., Gil, J., Ramírez De Ocariz, I. et al. (2003). In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp. Revista Española Quimioterapia 16, 227-32.
19. Sugar, A. M. & Liu, X. P. (1996). In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrobial Agents and Chemotherapy 40, 1314-6.
20. Graybill, J. R., Bocanegra, R., Najvar, L. K. et al. (1998). SCH56592 treatment of murine invasive aspergillosis. Journal of Antimicrobial Chemotherapy 42, 539-42.
21. Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W. et al. (2000). Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 44, 780-2.
22. Lozano-Chiu, M., Arikan, S., Paetznick, V. L. et al. (1999). Treatment of murine fusariosis with SCH 56592. Antimicrobial Agents and Chemotherapy 43, 589-91.
23. Lutz, J. E., Clemons, K. W., Aristizabal, B. H. et al. (1997). Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrobial Agents and Chemotherapy 41, 1558-61.
24. Sponsel, W. E., Graybill, J. R., Nevarez, H. L. et al. (2002). Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. British Journal Ophthalmology 86, 829-30.
25. Mellinghoff, I. K., Winston, D. J., Mukwaya, G. et al. (2002). Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clinical Infectious Diseases 34, 1648-50.
26. Dannaoui, E., Meis, J. F., Loebenberg, D. et al. (2003). Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrobial Agents and Chemotherapy 47, 3647-50.
27. National Committee for Clinical Laboratory Standards (2002). Reference Method for Broth Dilution Anfifungal Susceptibility Testing of Yeasts - Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA.
28. Barry, A. L., Pfaller, M. A., Brown, S. D. et al. (2000). Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. Journal of Clinical Microbiology 38, 3457-9.